CRF Health Unveils TrialMax ConMed™ for Oncology Trials
The identification of concomitant medication poses specific challenges in oncology data reporting.
CRF Health, a global provider of electronic Clinical Outcome Assessment (eCOA) solutions introduced a complete TrialMax® eCOA solution specifically for oncology clinical trials. The identification of concomitant medication poses specific challenges in oncology data reporting. To address this, CRF Health has incorporated its new TrialMax ConMed™ solution into the platform, allowing patients to report concomitant medication taken during a trial in real-time.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
